GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2007

Arius Inks Manufacturing Agreement with Avid Bioservices

  • Arius Research entered into a manufacturing supply and technology transfer agreement for its CD44 cancer stem cell antibody with Avid Bioservices. The company has already begun manufacturing a supply of the drug for clinical trials, which Arius plans to initiate in 2008.

    Arius is advancing the formal preclinical toxicology program for its lead CD44 cancer stem cell program, an anticancer antibody targeting a novel epitope of CD44 found in breast, colon, and prostate cancers.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?